exam 3 2008 - Your Name: _ MCMP 442 Exam 3 7:00 PM, EE 129...

Info iconThis preview shows pages 1–3. Sign up to view the full content.

View Full Document Right Arrow Icon
Your Name: ______________ MCMP 442 Exam 3 7:00 PM, EE 129 April 1, 2008 Instructions: 1. There are 9 pages including the cover and 29 questions. Please make sure that you have all of the pages before you start working on the examination. The LAST page (page 9) is a list of “alternate drug names” for your information; it may be more convenient for you to remove the last page (carefully!) for easier access as you work through the exam. 2. Please write your name at the top of this page NOW. Please fill out your information on the scan sheet NOW. 3. Be SURE to enter your answers to questions 1 – 26 on the scan sheet. The answers to questions 27 – 29 should be written directly on the exam sheet. 4. Read each question carefully before you start to answer it. If you have questions about the exam, please ask! Regrade policy: 1. If you feel that a question has not been graded correctly, return the exam within one week to Professor Borch. Attach a note about the error. The entire exam will be regraded. This means that you could gain or lose points. 2. If there is an error in addition of points, return the exam with a note to that effect. The examination will be re-totaled but not regraded.
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
2 (30 points) For each of the following questions, choose the single best answer. 1. Trastuzumab and lapatinib are similar in many respects for the treatment of breast cancer. Which of the following statements is not correct? a) Both drugs are useful in the treatment of HER2-overexpressing tumors b) Both drugs act by inhibiting HER2 tyrosine kinase c) Development of congestive heart failure is a risk for both drugs d) Both drugs can be used in combination with other cytotoxic agents e) Neither drug is highly effective in the treatment of ER+/PR+ tumors 2. Which of the following drugs has intrinsic pharmacologic activity (i.e., does not require a chemical transformation in order to generate the species that is biologically active)? a) Cisplatin b) Etoposide c) Amifostine d) Carmustine e) Dacarbazine 3. Which of the following drugs introduce(s) double strand breaks in DNA? a) Daunorubicin b) Irinotecan c) Bleomycin d) Vinorelbine e) a) and c) 4. What is the most likely mechanism that would explain the development of resistance to erlotinib in a tumor? a) Overexpression of DNA repair enzymes b) Overexpression of glutathione S-transferase c) Mutation of the epidermal growth factor receptor d) Overexpression of multidrug resistance protein e) Downregulation of CYP3A4 in the tumor 5. What is the mechanism by which leucovorin reduces the toxicity of methotrexate? a)
Background image of page 2
Image of page 3
This is the end of the preview. Sign up to access the rest of the document.

This note was uploaded on 03/11/2010 for the course MCMP 341 taught by Professor No during the Spring '10 term at Purdue University-West Lafayette.

Page1 / 9

exam 3 2008 - Your Name: _ MCMP 442 Exam 3 7:00 PM, EE 129...

This preview shows document pages 1 - 3. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online